(Q48030231)

7 February 2018

title

Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon (English)

1 reference

7 February 2018

1 reference

San Miguel R

1

1 reference

7 February 2018

Mar J

2

1 reference

7 February 2018

Cabasés JM

3

1 reference

7 February 2018

Guillén-Grima F

4

1 reference

7 February 2018

Buti M

5

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 March 2003

1 reference

7 February 2018

Alimentary Pharmacology & Therapeutics

published in

1 reference

7 February 2018

volume

17

1 reference

7 February 2018

issue

6

1 reference

7 February 2018

page(s)

765-773

1 reference

7 February 2018

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01494.X

Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01494.X

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01494.X

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01494.X

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01494.X

Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01494.X

Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01494.X

Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01494.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01494.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01494.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01494.X

Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01494.X

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01494.X

10.1046/J.1365-2036.2003.01494.X

21 January 2018

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018